β-Galactosidase-dependent metabolic glycoengineering of tumor cells for imaging and immunotherapy.
Yanchun LiLiang GongHaofei HongHan LinDan LiJie ShiZhifang ZhouZhimeng WuPublished in: Chemical communications (Cambridge, England) (2022)
A β-Gal-dependent metabolic glycoengineering strategy was developed for tumor cell-selective surface glycan imaging with high efficacy. Combined with an antibody-recruiting strategy, targeted immunotherapy was achieved successfully based on this strategy.